Health House International Limited (ASX:HHI) has signed an exclusive importation and distribution agreement with SmartwayPharmaceuticals Limited.
The Agreement will see Smartway import and supply cannabis-based products using its extensive regulatory knowledge and authorisations, and utilising Health House’s cannabis supply network.
Health House CEO, David Attwood, said the agreement will see Health House and Smartway import CBPMs (which are manufactured in accordance with Good Manufacturing Practice) into the UK for medicinal use. Health House and Smartway will distribute CBPMs via their extensive networks, initially throughout the UK.
“This agreement between Health House and Smartway will combine the strengths of each party in ensuring that healthcare professionals in the UK and ultimately, their patients have a broad access to the very best cannabis-based medicines from all over the world,” Mr Attwood said.
Smartway chief executive, Josh Cocklin, said his company is a global leader in designing and delivering ethical and compliant access programmes for products not yet licenced in a country.
“Smartway will leverage its regulatory knowledge and authorisations to enable efficient, safe and complaint distribution of these products. Smartway has a global supply network spanning over 100 countries and supplies directly to over 1,000 UK pharmacies.”
